Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes

Blood

Volumn 115, Issue 7, 2010, Pages 1374-1384

  Ugel, Stefano ^a,b   Scarselli, Elisa ^c   Iezzi, Manuela ^d   Mennuni, Carmela ^c   Pannellini, Tania ^d   Calvaruso, Francesco ^c   Cipriani, Barbara ^c   De Palma, Raffaele ^e   Ricci Vitiani, Lucia ^f   Peranzoni, Elisa ^a,g   Musiani, Piero ^d   Zanovello, Paola ^a,g   Bronte, Vincenzo ^g  

^a Department of Oncology and Surgical Sciences ^*  (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c Merck Research Laboratories   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; CANCER VACCINE; HLA A2 ANTIGEN; TERT PROTEIN, HUMAN; TERT PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE B CELL LYMPHOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BURKITT LYMPHOMA; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; CYTOARCHITECTURE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IN VIVO STUDY; LYMPHOCYTOPENIA; LYMPHOID ORGAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SPLEEN; SURVIVAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; VACCINATION; ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMAL; B LYMPHOCYTE; BONE MARROW CELL; C57BL MOUSE; CANCER TRANSPLANTATION; COLON TUMOR; DISEASE MODEL; GENETICS; IMMUNOLOGY; LUNG TUMOR; MELANOMA; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; SKIN TUMOR; TRANSPLANTATION; TUMOR CELL LINE;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES; BONE MARROW CELLS; CANCER VACCINES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HLA-A2 ANTIGEN; LUNG NEOPLASMS; LYMPHOPENIA; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; SPLEEN; T-LYMPHOCYTES; TELOMERASE;

EID: 77949905159     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-233270     Document Type: Article

References (39)

1. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955;102(2):157-177.
2. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-1680.
3. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-854.
4. Dudley ME,Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
5. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8(3):167-179.
6. + T-cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174(6):3798-3807.
7. Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 2007;67(21):10546-10555. (Pubitemid 350070831)
8. Vonderheide RH. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med. 2007;7(39):103-108.
9. Chen DY, Vance BA, Thompson LB, Domchek SM, Vonderheide RH. Differential lysis of tumors by polyclonal T-cell lines and T-cell clones specific for hTERT. Cancer Biol Ther. 2007;6(12):1991-1996.
10. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995;92(8):3439-3443.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111- 115. (Pubitemid 46067311)
12. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 1993;12(9):777-783. (Pubitemid 24295353)
13. Arai K, Masutomi K, Khurts S, Kaneko S, Kobayashi K, Murakami S. Two independent regions of human telomerase reverse transcriptase are important for its oligomerization and telomerase activity. J Biol Chem. 2002;277(10):8538- 8544.
14. Mennuni C, Ugel S, Mori F, et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res. 2008;68(23):9865-9874.
15. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T-cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30(6):1676-1682. (Pubitemid 30342810)
16. Draenert R, Altfeld M, Brander C, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T-cell responses. J Immunol Methods. 2003;275(1-2):19-29. (Pubitemid 36351539)
17. De Palma R, Marigo I, Del Galdo F, et al. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res. 2004;64(21):8068- 8076. (Pubitemid 39446945)
18. Wu Y, Tworkoski K, Michaud M, Madri JA. Bone marrow monocyte PECAM-1 deficiency elicits increased osteoclastogenesis resulting in trabecular bone loss. J Immunol. 2009;182(5):2672-2679.
19. Osati-Ashtiani F, King LE, Fraker PJ. Variance in the resistance of murine early bone marrow B cells to a deficiency in zinc. Immunology. 1998;94(1):94-100. (Pubitemid 28412793)
20. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004;64(6):2270-2305.
21. Raina K, Blouin MJ, Singh RP, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2007;67(22):11083-11091. (Pubitemid 350145939)
22. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383-393.
23. + T cells. J Exp Med. 2003;198(4):569-580.
24. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907-912. (Pubitemid 41396891)
25. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10(6):673-679.
26. Cappelletti M, Zampaglione I, Rizzuto G, Ciliberto G, La Monica N, Fattori E. Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. J Gene Med. 2003;5(4):324-332. (Pubitemid 40310384)
27. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T-cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97(9):4796-4801. (Pubitemid 30238637)
28. Thorn M, Wang M, Kloverpris H, et al. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother. 2007;56(11):1755-1763. (Pubitemid 47313080)
29. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299-308.
30. Terrin L, Rampazzo E, Pucciarelli S, et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008;14(22):7444-7451.
31. Grochola LF, Greither T, Taubert HW, et al. Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. Neoplasia. 2008;10(9):973-976.
32. Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie. 2008;90(1):173-180.
33. Bono AV, Montironi R, Pannellini T, et al. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice. Prostate Cancer Prostatic Dis. 2008;11(4):377-383.
34. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371(9625):1710-1721.
35. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105(23):8061-8066.
36. Tsuboi I, Hirabayashi Y, Harada T, et al. Predominant regeneration of B-cell lineage, instead of myeloid lineage, of the bone marrow after 1 Gy whole-body irradiation in mice: role of differential cytokine expression between B-cell stimulation by IL10, Flt3 ligand and IL7 and myeloid suppression by GM-CSF and SCF. Radiat Res. 2008;170(1):15-22.
37. Cabatingan MS, Schmidt MR, Sen R, Woodland RT. Naive B lymphocytes undergo homeostatic proliferation in response to B-cell deficit. J Immunol. 2002;169(12):6795-6805. (Pubitemid 36899264)
38. van Zelm MC, van der Burg M, van Dongen JJ. Homeostatic and maturation-associated proliferation in the peripheral B-cell compartment. Cell Cycle. 2007;6(23):2890-2895.
39. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)